Protein A Resin Market to Generate Revenue Worth $1,020.7 Million by 2030

  • Published: January 2020

The global protein A resin market generated an estimated value of $486.4 million in 2019, which is projected to reach $1,020.7 million by 2030, progressing at a CAGR of 7.0% during 2019–2030. Based on source, recombinant is expected to be the larger and faster-growing category during the forecast period. This can be mainly attributed to the fact that recombinant protein A ligands are the manipulated forms of protein that are used to generate large quantities of protein A resins.

Increasing Number of Collaborations and Agreements Is a Key Trend in the Market

Collaboration and partnership activities for the development of advanced next-generation protein A resins, and launch of new products are the key trends observed in the protein A resin market. For instance, in October 2019, Bio-Works Technologies AB has signed a distribution agreement with Hong Kong based Gene Company Ltd. According to the agreement, the latter company would import, store, distribute, market, promote, and sell Bio-Works Technologies AB’s products in China.

Increasing Research Activities to Address Unmet Medical Needs Are Likely to Boost the Market Growth

Increasing participation of public and private research organizations in protein research is boosting the growth of the protein A resin market, globally. Historically, the development of proteins and monoclonal antibodies as therapeutic agents was avoided by pharmaceutical companies, due to their size, low stability, poor delivery, and rate of degradation. However, the resurgence is taking place in the development of proteins and monoclonal antibodies as therapeutics for addressing unmet needs in various therapeutic areas, including cardiovascular diseases, metabolic diseases, infectious diseases, and oncology. This has led to increased attention on utilizing proteins that mimic the function of mediators involved in various pathologic processes.

Segmentation Analysis of Protein A Resin Market

Protein A Resin Market

  • The recombinant source of protein A resin held larger market share in 2019, mainly due to its increasing demand in the antibody purification.
  • Agarose-based matrix is expected to observe the fastest growth during the forecast period. This can be owing to the fact that agarose-based resins are obtained from natural source and contain ionic and hydrophobic groups that interact with the compound of interest.
  • The antibody purification category is expected to witness higher CAGR, of 7.2%, during 2019–2030. This can be primarily due to high production and increasing demand for antibodies, particularly monoclonal antibody for therapeutic application.
  • The biotechnology and pharmaceutical industries held larger market share, of 91.6%, in 2019. This is imputed to the fact that they use a large amount of protein A resins in the production process of antibody.

Geographical Analysis of Protein A Resin Market

Globally, North America is expected to account for the largest share in the protein A resin market by 2030, followed by Europe. Together, North America and Europe are expected to account for 70.9% market share in 2030. This can be mainly attributed to the increasing demand for protein-based therapeutics for treating chronic conditions and the rising number of the Food and Drug Administration (FDA) approved products in these regions. Additionally, presence of large-scale drug manufacturers, such as Gilead Sciences Inc. and Bayer AG, and the growing biopharma research industry are expected to contribute to the growth of market in the coming future.

Other regions, such as APAC, LATAM, and MEA, also hold considerable share in the protein A resin market, on account of increasing number of protein research activities, growing geriatric population, and rising demand for monoclonal antibodies for the treatment of chronic diseases.

  • In 2019, Japan held the largest share in the APAC protein A resin market. This is primarily attributed to the presence of well-established pharmaceutical industry and increasing R&D spending for the development of innovative and advanced drugs. Also, presence of pharmaceutical companies, such as Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Otsuka Holdings Co. Ltd., is supporting the growth of the market in the country.
  • Brazil is projected to be the largest and the fastest-growing protein A resin market in the LATAM region during the forecast period. The growth in the market can be mainly attributed to the increasing prevalence of chronic diseases and rising healthcare expenditure.
  • In Saudi Arabia, owing to the economic growth, rising disposable income, and increasing investments by small- and mid-sized private companies in protein research, the protein A resin market is projected to grow at the fastest rate in the MEA region.

Competitive Landscape of Protein A Resin Market

The protein A resin market is consolidated in nature with the presence of giant players, such as GE Healthcare, Merck KGaA, Thermo Fisher Scientific Inc., Purolite Corporation, Tosoh Corporation, Novasep Holding SAS, and Repligen Corporation.

In recent years, major players operating in the global protein A resin market have adopted acquisition as a key strategy to increase their protein A resin related product portfolio. For instance, in April 2016, Repligen Corporation acquired Atoll GmBH, a German based company, to expand its pre-packed column chromatography portfolio in high throughput process development screening. The acquisition was made in $9.1 million in cash and 538,700 shares of Repligen common stock.

Browse report overview with detailed TOC on "Protein A Resin Market Research Report: By Source (Recombinant, Natural), Matrix (Agarose-Based, Glass or Silica-Based, Organic Polymer-Based), Application (Antibody Purification, Immunoprecipitation), End User (Biotechnology and Pharmaceutical Industries, Academic Institutes and Research Laboratories) – Industry Size, Share, Trends and Forecast to 2030" at:

Similarly, in April 2015, Tosoh Corporation acquired a Mumbai-based clinical diagnostic company Lilac Medicare Pvt. Ltd. to establish its own bioscience operation in India. The agreement expanded the bioscience operation and bioscience product portfolio in India.

Some other important players operating in the protein A resin market are Bio-Works Technologies AB, Amikozen Co. Ltd., Bio-Rad Laboratories Inc., Expedeon AG, GenScript Biotech Corporation, and Kaneka Corporation.